<description>&lt;p&gt;Every year, flu vaccine manufacturers have to guess what strains to target next season, with varying success. &lt;a href="https://www.cidara.com/" rel="noopener noreferrer" target="_blank"&gt;Cidara Therapeutics&lt;/a&gt; believes it may have a better alternative. President and CEO Jeff Stein explains how Cidara's laser-like focus on developing CD388, a single-dose antiviral targeting all flu strains, has brought the 40-person company on the verge of a public health breakthrough.&lt;/p&gt;&lt;p&gt;&lt;a href="https://www.cidara.com/news/cidara-therapeutics-announces-positive-topline-results-from-its-phase-2b-navigate-trial-evaluating-cd388-a-non-vaccine-preventative-of-seasonal-influenza/" rel="noopener noreferrer" target="_blank"&gt;Cidara announces positive topline results from its phase 2b NAVIGATE trial evaluating CD388&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;a href="https://www.cidara.com/about/#leadership" rel="noopener noreferrer" target="_blank"&gt;President and CEO Jeff Stein Bio&lt;/a&gt;&lt;/p&gt;</description>

Pathfinders in Biopharma

RBC Capital Markets

Cidara’s pursuit of universal flu protection with a single dose

JUL 11, 202512 MIN
Pathfinders in Biopharma

Cidara’s pursuit of universal flu protection with a single dose

JUL 11, 202512 MIN

Description

Every year, flu vaccine manufacturers have to guess what strains to target next season, with varying success. Cidara Therapeutics believes it may have a better alternative. President and CEO Jeff Stein explains how Cidara's laser-like focus on developing CD388, a single-dose antiviral targeting all flu strains, has brought the 40-person company on the verge of a public health breakthrough.Cidara announces positive topline results from its phase 2b NAVIGATE trial evaluating CD388President and CEO Jeff Stein Bio